Esuberaprost Sodium

N/A

Report date: 2024/06/02 20:00:06
NME

Base Information

Drug NameEsuberaprost Sodium
Drug Alias NameBeraprost Sodium 314d Modified Release艾司贝前列素esuberaprostum艾苏贝前列素esuberaprost +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid IP receptor agonists
TargetsProstanoid IP receptor
Therapy Area/IndicationsPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesToray Industries Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLung Biotechnology PbcLundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
Active IndicationsN/A
Inactive IndicationsPulmonary Arterial Hypertension

Other Information

ATC CodeN/A
Related LinksKEGG